Conclusion: why now may be the right time <\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n\nPCaVision offers a new way to make diagnostics more efficient, faster, and accessible. The Dutch MedTech company is developing an AI-powered prostate cancer diagnostic tool based on ultrasound<\/strong>, enabling urologists to make a diagnosis in a single session —without MRI and without radiologists. <\/p>\n\n\n\nIn doing so, PCaVision addresses a care gap that is only set to grow in the coming years. That’s why this project is also compelling for investors: it combines medical benefit, impact investing in healthcare, and a scalable SaaS model with strong growth potential. <\/p>\n\n\n\n
<\/div>\n\n\n\n
<\/span>Prostate cancer – an urgent health challenge<\/strong> <\/span><\/h2>\n\n\n\nA common disease. A diagnosis that takes time and energy. <\/strong><\/p>\n\n\n\n<\/div>\n\n\n\n
\n
\n
\n
Prostate cancer is one of the most frequently diagnosed cancers in men. Global demand for diagnostic procedures is growing by about 10% each year. By 2040, demand is expected to double. Reasons include: <\/p>\n\n\n\n
\nAn aging population <\/li>\n\n\n\n Expanded preventive care programs <\/li>\n\n\n\n Growing awareness of prostate cancer screening <\/li>\n<\/ul>\n<\/div>\n<\/div>\n\n\n\n<\/div>\n\n\n\n
1. Waiting for the exam – often for weeks<\/strong> <\/p>\n\n\n\nSuspected prostate cancer is stressful. Many patients wait weeks for an MRI appointment due to limited radiology capacity. This creates uncertainty and delays potential treatment.<\/p>\n\n\n\n
2. Multiple appointments, more effort<\/strong><\/p>\n\n\n\nDThe standard process looks like this: <\/p>\n\n\n\n
\nSuspicion raised during a urologist visit<\/li>\n<\/ul>\n\n\n\n\nReferral for MRI <\/li>\n<\/ul>\n\n\n\n\nMRI result from a radiologist <\/li>\n<\/ul>\n\n\n\n\nFollow-up with the urologist <\/li>\n<\/ul>\n\n\n\n\nTargeted biopsy <\/li>\n<\/ul>\n\n\n\nThe result: delays, extra steps, and numerous appointments. <\/p>\n\n\n\n
3.Invasive procedures, often unnecessary<\/strong><\/strong> <\/p>\n\n\n\nThe alternative to MRI is a systematic biopsy involving multiple tissue samples—even if no clinically relevant cancer is found. This places a physical and mental burden on patients.<\/p>\n\n\n\n
4. Capacity issues across the system<\/strong><\/p>\n\n\n\nUrology and radiology departments are already stretched thin. Overloaded diagnostic structures mean longer wait times and case numbers continue to rise. <\/p>\n\n\n\n
In short:<\/strong> the system is reaching its limits, and the ones suffering are the men who need clarity. <\/p>\n\n\n\n<\/div>\n\n\n\n
<\/span>PCaVision streamlines the lengthy diagnostic process<\/span><\/h2>\n\n\n\nPCaVision accelerates diagnosis by combining AI and ultrasound. The technology is clinically validated, CE-certified, and already in use in pilot clinics. <\/p>\n\n\n\n
\n
\n
\n
<\/p>\n\n\n\n
How does it work in practice? <\/h3>\n\n\n\n\nThe urologist uses a standard 3D\/4D ultrasound probe<\/li>\n\n\n\n PCaVision analyzes the data automatically<\/li>\n\n\n\n The software generates a color-coded heatmap highlighting suspicious areas<\/li>\n<\/ul>\n\n\n\nThe physician can perform targeted biopsies in the same session<\/p>\n<\/div>\n<\/div>\n\n\n\n
A diagnostic process that used to take weeks is now completed in just 20–30 minutes. <\/strong> <\/p>\n\n\n\n<\/div>\n\n\n\n
<\/span>Benefits for patients: clearer, less stressful, faster diagnosis<\/strong> <\/strong> <\/span><\/h2>\n\n\n\n1. Faster diagnosis enables earlier treatment<\/strong>2. Less physical strain<\/strong>\nFewer punctures<\/li>\n\n\n\n The physician can perform targeted biopsies in the same session<\/li>\n\n\n\n Less post-procedure discomfort<\/li>\n<\/ul>\n\n\n\nStudies show unnecessary biopsies can be reduced by up to 75%. <\/p>\n\n\n\n
3. No additional appointments, everything in one session<\/strong> 4. MRI-level diagnostic quality, but more accessible<\/strong> 5. Greater equity in access to care<\/strong> <\/div>\n\n\n\n
In short: PCaVision gives patients earlier clarity, reduces their burden, improves access to diagnostics and relieves the pressure on the healthcare system. <\/strong><\/p>\n\n\n\n<\/div>\n\n\n\n
<\/span>Why this matters to investors<\/strong> <\/span><\/h2>\n\n\n\nBecause patient benefits are directly tied to economic potential. The bigger the medical problem, the stronger the market and the clearer the need for a better solution. <\/p>\n\n\n\n
1. A large, growing market<\/strong> This is a huge market, and PCaVision addresses a critical bottleneck. <\/p>\n\n\n\n
2. A solution that truly relieves the system<\/strong> For clinics, that translates to: <\/p>\n\n\n\n
\nFaster workflows <\/li>\n\n\n\n Less dependency on MRI <\/li>\n\n\n\n Economic benefits <\/li>\n<\/ul>\n\n\n\nA product that cuts costs while improving care quality has strong chances for widespread adoption. <\/p>\n\n\n\n
3. A scalable SaaS business model<\/strong> \nRecurring revenue <\/li>\n\n\n\n Predictable income <\/li>\n\n\n\n High margins <\/li>\n\n\n\n Low variable costs <\/li>\n\n\n\n Strong scalability <\/li>\n<\/ul>\n\n\n\nEvery clinic becomes a long-term revenue driver. <\/p>\n\n\n\n
4. Clinically validated, CE-certified, early customers onboard<\/strong> 5. Strong institutional backers<\/strong> \nNLC Health Impact Fund <\/li>\n\n\n\n CbusineZ <\/li>\n\n\n\n TU\/e Holding<\/li>\n\n\n\n Family offices and experienced angel investors <\/li>\n<\/ul>\n\n\n\nPrivate investors participate via Invesdor on the same preferred share terms as these institutional investors, meaning equal economic rights. <\/p>\n\n\n\n
6. Impact investing with measurable value<\/strong> \nSpeeds up diagnoses <\/li>\n\n\n\n Reduces unnecessary procedures<\/li>\n\n\n\n Improves access to care <\/li>\n\n\n\n Relieves pressure on healthcare systems <\/li>\n<\/ul>\n\n\n\n… fulfilling SDG 3: “Good Health and Well-being.”
7. Attractive exit options in MedTech<\/strong> \nStrategic acquisition by imaging or diagnostics giants <\/li>\n\n\n\n Series B funding at a higher valuation<\/li>\n\n\n\n Regional licensing or distribution partnerships <\/li>\n<\/ul>\n\n\n\nAs market adoption grows, so does company value and investor potential. <\/p>\n\n\n\n
What matters<\/strong>: <\/p>\n\n\n\nInvesting in growth companies carries risk, including total loss.
A rational checklist: <\/p>\n\n\n\n
\nIs the market big enough? → Yes: growing, driven by demographics and medical need <\/li>\n<\/ul>\n\n\n\n\nDoes the company solve a real problem? → Yes: a genuine and growing care gap <\/li>\n<\/ul>\n\n\n\n\nIs the product validated and market-ready? → Yes: CE-certified, early clinics onboard, strong data <\/li>\n<\/ul>\n\n\n\n\nIs the business model scalable? → Yes: SaaS with recurring revenue <\/li>\n<\/ul>\n\n\n\n\nAre experienced investors involved? → Yes: institutional and strategic partners <\/li>\n<\/ul>\n\n\n\nFor many investors, PCaVision is compelling: it combines medical value, measurable impact, and a scalable tech model, a rare combination in the MedTech space. <\/p>\n\n\n\n